Iktos and Pierre Fabre Laboratories have announced an integrated drug discovery collaboration to identify and develop novel small-molecule drug candidates for an undisclosed oncology target. Under the agreement, Iktos will leverage its AI-driven generative design platform and automated chemistry technologies to accelerate the discovery of optimized candidates. Pierre Fabre Laboratories will contribute its expertise in oncology research and preclinical development to guide the selection and progression of these molecules. By integrating generative AI with automated synthesis, the partnership aims to improve the probability of success and accelerate the delivery of innovative therapeutics for unmet needs in oncology, further solidifying Iktos’ role as a strategic partner in AI-powered R&D.
